当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Bivigam, Immune Globulin Intravenous (Human)
申请企业
ADMA Biologics, Inc.
药品名称
Bivigam, Immune Globulin Intravenous (Human)
承诺描述
Conduct a Prospective, non-interventional, active-control, observational safety study to further assess the potential risk of hypotension, hepatic and renal impairment in Biotest-IGIV-treated patients with primary humoral immunodeficiency (PI).